Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

NCT01933334 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis

Interventions

DRUG: Pirfenidone

Sponsor

Genentech, Inc.